Combination Therapy Study for Acromegaly
This is a 12 month study. During the first 6 months, patients receive combination therapy (Somatostatin Analog + Pegvisomant) and during the second 6 months, they are on Pegvisomant only.
Somatostatin analogs and Pegvisomant lower GH (Growth Hormone), by two very different mechanisms. In this study, we are investigating, the most effective way to combine these drugs, in order to determine the combination that has maximum efficacy, least side-effects, and is most cost-effective.
The study is being performed at Cedars Sinai Medical Center in Los Angeles. Participants will be required to travel to Cedars Sinai Medical Center in Los Angeles 3 times over the 12 month study period (at the study initiation, middle(6 months) and end of the study(12 months). All travel/accommodation costs for the visits are covered by the study. Monthly blood tests will be done at a local quest lab in the patient’s hometown. Pegvisomant will be shipped to the patient’s home and dose adjustments will be made, depending on the blood test results.
Visits, monthly blood tests, drug dose adjustments and drug shipment will be coordinated by physicians and research staff at Cedars Sinai Medical Center.